

## Exhibit A

### CURRICULUM VITAE

**Victor L. SEREBRUANY, M.D., Ph.D.**

*October, 2004*

Work: HeartDrug™ Research Laboratories,  
Osler Medical Center,  
7600 Osler Drive, Suite 307  
Towson, MD, 21204  
(410) 847-9490- (office)  
(410) 847- 9491- (laboratory)  
(443) 583-0205- (facsimile)  
(410) 274-2405- (cellular phone)  
heartdrug@aol.com (E-mail)  
[www.heartdrug.com](http://www.heartdrug.com) (WEB)

#### ***Education :***

1984-1989 <b>Ph.D.</b>	Pharmacology. Thesis : “Hemostatic disorders and their pharmaceutical correction in children with nephrotic syndrome”. Institute of Pediatrics & Children’s Surgery (Moscow, USSR)
1982-1984	Postdoctoral Fellowship in Perinatology. Institute for Postgraduate Medical Education (Moscow)
1976-1982 <b>M.D.</b>	Second State Medical Institute (Moscow)

#### ***Additional training:***

1991	Accounting, economics, industrial psychology	Johns Hopkins University ( Baltimore, MD )
1988	Business, politics, international trade	Political State University ( Moscow, Russia )

### ***Professional Experience :***

- 2000 - present ***Owner***, HeartDrug™ Research, LLC
- 1999 – present ***Editor for Americas***, “HeartDrug™” International Journal for Cardiovascular Clinical Trials (Karger Publishers, Basel, Switzerland)
- 1999 - 2003 ***Assistant Professor***, Department of Medicine, Johns Hopkins University
- 1997 - 2003 Research ***Director***, Sinai Center for Thrombosis Research.
- 1997 – 2000 ***Managing Partner***, “HeartDrug™ Research, LLC”
- 1995 –1997 ***Director***, Cardiovascular Research. Union Memorial Hospital.
- 1994 - 1995 ***Research Associate*** , Division of Cardiology, University of Maryland
- 1992 - 1994 ***Postdoctoral Fellow***, Division of Cardiology, University of Maryland
- 1991 - 1992 ***Sr. Research Assistant*** , Division of Pediatric Nephrology  
Johns Hopkins University
- 1989 – 1991 ***Sr. Research Scientist.***, Head, Division of Clinical Pharmacology.  
Institute of Pediatrics & Children’s Surgery, Moscow, USSR
- 1984 - 1989 ***Research Scientist.***, Division of Pediatric Nephrology  
Institute of Pediatrics & Children’s Surgery, Moscow, USSR

### ***Awards and Honors:***

- 2002 Pfizer Established Investigator Award
- 1991 Bristol-Myers Squibb Stipend
- 1990 International Pediatric Nephrology Association Award
- 1989 Bristol-Myers Squibb Young Investigator Award

### ***Professional Societies :***

American Medical Association  
 American Federation for Clinical Research  
 American Heart Association ( Council for Arteriosclerosis, Thrombosis  
 and Vascular Biology )  
 International Society on Thrombosis and Haemostasis

### ***Consultant :***

DAKO, PharMingen, Becton Dickinson, Pfizer, Bristol-Myers Squibb, Sanofi Synthelabo.  
 Novartis, Boehringer Ingelheim, McNeil, NPS Pharma, Guilford

### ***Reviewer :***

JAMA, Circulation, Journal of American College of Cardiology, Stroke, American Journal of Cardiology, American Heart Journal, American Journal of Respiratory & Critical Care Medicine, Thrombosis Research, Journal of Cardiovascular Pharmacology, International Journal of Cardiology, Nephron, Magnesium Research, Atherosclerosis, Acta Psychiatrica Scandinavica, Clinical Pharmacology, Drugs in R&D, Pediatric Blood & Cancer, Blood Coagulation & Fibrinolysis

### ***Research :***

Approved for 2004/2008 - Aggrenox versus clopidogrel for second stroke prevention. The Compliance Substudy for the PROFESS trial (Boehringer Ingelheim).

Approved for 2004/2005 – Hemostatic Dysfunction in Acute Spontaneous Intracerebral Hemorrhage Role - Co-PI; PI- Wendy Ziai, MD (Johns Hopkins University)

Approved for 2004/2005 - Effect of clopidogrel and aspirin combination versus aspirin alone on platelets in patients with diabetes mellitus (PLUTO-DM Trial) (Sanofi, Bristol-Myers Squibb)

Approved for 2004/2005 – Effect of escalating doses of aspirin on platelet, inflammatory, and endothelial biomarkers in patients with coronary artery disease and metabolic syndrome Role - Co-PI; PI- Prof. Charles H. Hennekens. (Bayer)

Approved for 2004/2005 – Effect of Aggrenox, Telmisartan, their combination, and clopidogrel + aspirin on platelets in patients with diabetes mellitus. (Boehringer-Ingelheim).

Approved for 2005 - Effect of clopidogrel and aspirin combination versus aspirin alone on platelets in patients with peripheral vascular disease (PLUTO-PVD Trial) (Sanofi, Bristol-Myers Squibb)

- 2004 - present Evaluation of the novel ADP cartridge before and after clopidogrel in patients with documented coronary artery disease (Accumetrics)
- 2004 – present – Fluorometric measurements of dipyridamole for human and animal R&D studies (Worldwide Core Laboratory). (Boehringer Ingelheim)
- 2004-present – Effects of tirofiban on surface platelet receptors expression in patients with diabetes mellitus, and those undergoing coronary interventions (Guilford)
- 2004 - present Evaluation of the propyl-gallate versus *Verify Now*<sup>TM</sup> cartridges in patients already receiving aspirin (Accumetrics)
- 2004 – present – Effect of protectant V on platelet – endothelial biomarkers in patients with coronary artery disease. The ARISE Platelet Substudy (Atherogenics).
- 2003 – 2004 – Effect of different doses of aspirin on bleeding complications. The meta-analyses of controlled clinical trials (McNeil).
- 2003 – present - Platelet function after different doses of CS-747 versus clopidogrel in patients undergoing coronary stenting (The JUMBO-TIMI-26 Platelet Substudy) (Lilly)
- 2003 – present - Assessment of the platelet response variability to clopidogrel. (Sanofi, Bristol-Myers Squibb).
- 2003 – present - Treatment of aspirin resistance with Aggrenox in patients with TIA and ischemic stroke (the in vitro study). (Boehringer Ingelheim)
- 2003 - present - Effects of escalating doses of valsartan (Diovan©) on platelets in patients with mild to moderate hypertension: Valsartan Inhibits Platelets (VIP Trial) Novartis
- 2003 – present - Effects of escitalopram on platelet function in humans (Lundbeck AG)
- 2003 - present - Effects of citalopram (Celexa®) versus placebo on platelets in patients with depression and coronary artery disease (CREATE) (Montreal Heart Institute)
- 2002 – 2004 - Effect of clopidogrel and aspirin combination versus aspirin alone on platelets in patients with ischemic stroke or TIA (Sanofi, Bristol-Myers Squibb).
- 2002 – 2003 - Effects of Aggrenox on platelet function in patients after TIA or stroke (AGATE), (Boehringer Ingelheim)
- 2002 - 2003 - Interactions of atorvastatin and clopidogrel in patients undergoing coronary stenting (INTERACTION trial) (Pfizer).
- 2002 – 2003 - Effects of in vitro valsartan and its major metabolite valeryl – 4 hydroxy valsartan on human platelets (Novartis)

- 2001 – 2002 - Effect of Aggrenox versus conventional aspirin on bleeding risks, and timing of platelet inhibition (Boehringer Ingelheim)
- 2001- 2002 - Evaluation of the Epinephrine/iso-TRAP cartridge in arterial and venous samples in patients undergoing coronary interventions (Accumetrics)
- 2001- 2002 - Evaluation of the Precision of the Propyl Galat Cartridge in volunteers treated with single dose aspirin (Accumetrics,)
- 2001- 2002 - Evaluation of the Dual RPFA ADP Cartridge in subjects treated with clopidogrel or ticlopidine (Accumetrics, Inc.)
- 2001- 2002 - Evaluation of the Dual RPFA ADP/iso-TRAP Cartridge in subjects treated with integrilin, and tirofiban (Accumetrics)
- 2000-2002 - Effect of clopidogrel + aspirin versus aspirin alone on platelets in patients with congestive heart failure The PLUTO-CHF study (Bristol-Myers Squibb, Sanofi).
- 2000-2001 Effect of aerobic exercise on plasma levels of atrial natriuretic peptide and norepinephrine in patients with heart failure (Duke Clinical Research Institute).
- 2000-2002 - The *in vitro* effects of different thrombolytic agents on platelet aggregation, and surface receptor expression (Genentech, HeartDrug Research, LLC).
- 1999-2001 - Assessment of platelet-endothelial interactions in patients with acute myocardial infarction undergoing thrombolytic therapy with t-PA and TNK (ASSENT-II Platelet Study). (Genentech, HeartDrug Research, LLC).
- 1999–2000 - Assessment of platelet function with the Platelet Function Analyzer (PFA-100™) in patients with acute coronary syndromes, and after oral GP IIb/IIIa blockade (Dade-Behring, HeartDrug Research, LLC)
- 1999 – 2000 - Comparison of the Rapid Platelet Function Analyzer versus conventional aggregometry in patients with coronary artery disease after oral GP IIb/IIIa blockade (Accumetrics, HeartDrug Research, LLC)
- 1999 – 2000 - Assessment of platelet contractile force with the Platelet Analyzer in patients with acute coronary syndromes, and after oral GP IIb/IIIa blockade (Hemodine, HeartDrug Research, LLC)
- 1999 – present - Diagnostic utility of the platelet receptor expression by flow cytometry in patients with acute coronary syndromes, chest pain, and heart failure (Beckton – Dickinson, HeartDrug Research, LLC)
- 1998 - 2000 - Platelet function in patients with chronic heart failure (EPCOT trial) (Duke Clinical Research Institute, HeartDrug Research, L.L.C.).

- 1998 - 1999 - Effect of DMP 754-010 versus aspirin on platelet aggregation, major receptor expression, release reactions, and thrombin generation in patients with acute coronary syndromes. (DuPont )
- 1998 –1999 - Use of coenzyme Q10 (Ubiquinone™) in patients with acute coronary syndromes.(University of Copenhagen, Pharma Nord)
- 1998 - 1999 - Assessment of platelet activation and novel necrosis markers in patients with acute coronary syndromes (Zurich University)
- 1998 - 2000 - Effect of azytromycin in patients with *Chlamydia pneumoniae* - associated coronary artery disease on endothelial function (Pfizer, University of Utah)
- 1998 - 2000 - Optimal timing of clopidogrel (Plavix®) loading regimen in patients undergoing coronary stenting. PRONTO trial. (Bristol - Myers Squibb, Sanofi).
- 1997 - 2003 - Effects of sertraline (Zoloft®) versus placebo on platelet/endothelial biomarkers in patients with depression after acute myocardial infarction (SADHART Platelet Substudy). (Pfizer)
- 1997 – 1998 - Effects of ReoPro and/or reteplase on platelet aggregation, GP IIb/IIIa, and P-selectin expression in patients with acute myocardial infarction (SPEED) (Centocor)
- 1996 – 1998 - Crossreactivity of the major platelet surface receptors between humans and Yorkshire swine (DAKO)
- 1997 – 1998 - Diagnostic utility of platelet and soluble P-selectin in patients with acute coronary syndromes. MAPS-1 trial. (Centocor)
- 1996- 1997 - Effects of Orbofiban on major surface platelet receptors rather than GP IIb/IIIa in patients with stabilized ischemic syndromes (Searle)
- 1996-1997 - Effect of r-PA vs. t-PA on the platelet status in patients with myocardial infarction. The GUSTO-III Platelet Substudy. (Boehringer Mannheim).
- 1992-1995 - Cardiovascular applications of leumedins (Scios - Nova)
- 1992- 1996 - Effect of ubiquinone (CoQ10 ®) on myocardial reperfusion injury, infarct size and platelet function. (Pharma Nord)
- 1993- 1996 - Coronary endothelin - I level in patients with unstable angina (Merck)
- 1993-1995 - Alteplase® vs. Abbokinase® vs. BM. 06.022 on platelet function and coagulation during myocardial infarction (Abbott)

1991-1992 - Genetic alterations in human complement alleles in children with nephropathies and their families (Bristol-Myers Squibb )

1986-1988 - Effects of pentoxifylline (Trental ®) on renal function and hemorheology in children with nephrotic syndrome. (Bayer)

1984-1988 - Management of hypertension with captopril (Capoten ®) therapy in pregnant women with preeclampsia. (Squibb & Sons)

### ***Mentorship :***

#### ***Post doctoral fellows:***

Alex Malinin, M.D., 2000-present

Alik Janishvili, M.D., 2001- 2002, Resident in Surgery, Montefiore Hospital, New York, NY

Selva Muguresan, Ph.D., 1997-1999. Current position: Research Director, Cell Trends, Inc.; Frederick, MD

Sergey Y. Fuzaylov, M.D. 1998-2000. Current Position: Medical Resident in Anesthesiology. University of Massachusetts, Worcester, MA

#### ***Graduate students:***

Kevin Callahan, Physiology / Pharmacology, Ph.D., 2000-2002

#### ***Medical Residents:***

Girish Nair, M.D., 1998-2000. Current position: Cardiology Fellow, Wake Forest University, Winston- Salem, NC

Husam Semaan, M.D., 1997-2000. Current Position : Family practice physician, Cambridge, MD

Christopher Davis, M.D., 1998-2001. Current Position: Cardiology Fellow, University of Virginia, Charlottesville, VA

Marcus McKenzie, M.D., 1998-2002. Current Position: Cardiology Fellow, Georgetown University, Washington, DC

Andrew Meister, M.D., 1999-2002

Johnathan Hefner, M.D, 2000-2002

#### ***Pre-doctoral trainees:***

<u>Soni Oei</u>	1992-1993, medical student
<u>Matthew Schlossberg</u>	1992-1994, medical student
<u>Lisa Edenbaum</u>	1993-1995, medical student
<u>Matthew Greber</u>	1994-1995, medical student
<u>Steven Komjathy</u>	1993-1995, medical student
<u>Douglas Levine</u>	1998-1999, high school student
<u>Eric Horowitz</u>	2000-2001, graduate student
<u>Benjamin Oshrine</u>	2000-present, medical student

***Patents:***

1. Determining a treatment plan for patients undergoing thrombotic event by monitoring P-selectin (USN 6,230,713; issued May 15, 2001). Ownership: BTG International, Dalesandro/Gurbel/Serebruany
2. Methods for inhibiting platelet activation with selective serotonin reuptake inhibitors (USN 6,245,782; issued June 12, 2001). Ownership: HeartDrug
3. Methods of treatment of thrombotic events (USN 10/106,958, filed March 25, 2002) Ownership: HeartDrug/BTG International
4. Methods for inhibiting platelet activity with valsartan, and valeryl 4-hydroxy-valsartan (USN 60/395,014 filed August 1, 2002). Ownership: Novartis/HeartDrug
5. Methods for inhibiting platelet activation with selective serotonin reuptake inhibitors (USN 6,552,014; issued April 22, 2003). Ownership: HeartDrug
6. Use of dipyridamole and mopidamole for treatment and prevention of thromboembolic disease and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors (USN60/465,168, filed April 24, 2003). Ownership – Boehringer Ingelheim/ HeartDrug
7. Method for inhibiting platelet activation and thrombin generation with statins (HeartDrug/Pfizer 10 / 811, 563)

***Publications:*****Books/Book chapters :**

1. Axelrod VG, Serebruany VL, Medvedev MV. Use of transcutaneous PaO<sub>2</sub> for estimation of breathing in the newborns undergoing negative pressure. In : “Actual aspects of human adaptive reactions in experimental and clinical practice”. V.V.Gavrushov (Editor) Moscow, “Progress” 1986; pp. 126-148.
2. Serebruany VL, Medvedev MV. Ultrasound antenatal diagnosis of urinary tract malformations in fetus. In : “Congenital and hereditary diseases in children.” Moscow/Berlin, M.S. Ignatova, Z.Schults (Editors) 1988; pp. 148-154.
3. Levitzky SV, Barkagan LZ, Serebruany VL. “Thrombophilia in children : Pathogenesis; Diagnosis; Pharmacology.” Practical guide for doctors. 1989, Moscow “Medicina”, 83p.
4. Serebruany V.L. “Hi, America !” First legal immigration guide for Russians. DIANE Publishing, Inc. 1995; 256p.
5. Gurbel PA, Kologie F, Serebruany VL, Mergner WJ. Myocardial cell injury during ischemia and reflow. In : Principals of Medical Biology. Volume 13. Bittar EE, Bittar N. (Editors) JAI Press, Inc. 1998, pp. 127-166.



## Original Articles

### A. Published :

1. Burakova VB, Musikantova VS, Sydorova TA, Serebruany V.L. Clinical and morphological correlations in premature newborns with intraventricular hemorrhage. *Pediatrics* 1985; 9 : 10-13.
2. Medvedev M.V., Serebruany V.L., Machinskaya E.A. Antenatal diagnosis of Ebshtein syndrome using echocardiography. *Pediatrics* 1986; 11 : 68-69.
3. Medvedev MV, Serebruany VL, Axelrod VG. Antenatal ultrasound diagnosis of combined heart defect in fetus. *Vopr. Ochr. Mater. & Det* 1987; 1 : 72-73.
4. Serebruany VL, Barkagan LZ Hemostatic abnormalities and pharmacology of the nephrotic syndrome in childhood. *Pediatrics* 1987; 2 : 91-94.
5. Serebruany VL, Ignatova MS, Degtyareva EM. Thrombophilia in children with the nephrotic syndrome. *Pediatrics* 1989; 1 : 49-53.
6. Svetlov SI, Serebruany VL Platelet-activating factor: biochemical and pathophysiological aspects. *Pathophysiol Exper Ther* 1989; 1 : 70-75.
7. Svetlov SI, Burova VYa, Serebruany VL, Veltischev YE. Morphological changes in pulmonary and kidney tissues, induced by intravenous PAF and blocked by verapamil injections. *Bull Exper Biol Med*, 1989; 58 : 276-279.
8. Serebruany VL, Christenson MJ, Pescetti J, McLean R H. Hypoproteinemia in the hemolytic-uremic syndrome of childhood. *Pediatric Nephrol* 1993; 7 : 72-73.
9. Herzog WR, Atar D, Gurbel PA, Vogel RA, Schlossberg ML, Serebruany VL. Effect of magnesium infusion on platelet aggregation in swine. *Magnes Res* 1993; 4:349-353.
10. Gurbel PA, Anderson RD, MacCord CS, Scott HJ, Serebruany VL, Herzog WR. Accelerated intravenous dosing of recombinant tissue plasminogen activator causes rapid but unstable reperfusion in canine model of acute myocardial infarction. *Cor Artery Dis* 1994; 5:929-936.
11. Atar D, Serebruany V, Poulton J, Godard J, Sneider A, Herzog W. Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion. *J Cardiovasc Pharm* 1994; 24: 603-611.
12. Herzog WR, Schlossberg ML, Mortensen SA, Serebruany VL. Effect of Coenzyme Q10 supplementation on platelet aggregability in swine. *CoQ10 Res Biol Med* 1995; 3 : 5 - 8.
13. Gurbel PA, Serebruany VL, Komjathy SF, Collins ME, Sane DC, Scott HJ, Schlossberg ML, Herzog WR. Regional and systemic platelet function is altered by myocardial ischemia-reperfusion. *J Thromb Thrombolys* 1995; 1:187-194.
14. Serebruany VL, Herzog WR, Gurbel PA, Schlossberg ML, Scott HJ, Vogel RA. NPC 15669, an anti-inflammatory leucine derivative reduces *in vitro* platelet aggregability in both swine and human plasma. *J Thromb Thrombolys* 1995; 1:171-178.
15. Herzog WR, Gurbel PA, Vogel RA, Schlossberg ML, Scott HJ, Schneider AI, Serebruany VL. Effects of NPC 15669 an anti-inflammatory leucine derivative on myocardial stunning and pre-conditioned infarction size in swine. *J Thromb Thrombolys* 1995; 1:163-170.
16. Herzog WR, Schlossberg ML, MacMurdy KS, Edenbaum LR, Gerber MG, Vogel RA, Serebruany VL. Timing of magnesium therapy affects experimental infarct size. *Circulation* 1995; 92: 2622-2626.

17. Serebruany VL, Herzog WR, Atamas SP, Gurbel PA, Paulsen G, Mortensen SA, Folkers K. Hemostatic Changes after dietary Coenzyme Q10 supplementation in swine. *J Cardiovasc Pharm* 1996; 28: 175-181.
18. Herzog WR, Serebruany VL. How magnesium therapy may influence clinical outcome in acute myocardial infarction: review of potential mechanisms. *Coron Artery Dis* 1996; 7: 364-371.
19. Serebruany VL, Herzog WR, Gurbel PA. Serial changes of natural antithrombotics during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. *Blood Coag Fibrinol* 1996; 7: 632-640.
20. Gurbel PA, Serebruany VL, Komjathy SF, Collins ME, Bittar GD, Schlossberg ML, Mergner W. Pretreatment with an inhibitor of Mac-1 alters regional and systemic platelet function during ischemia - reperfusion in swine. *Pharmacology* 1996; 53: 79-86.
21. Serebruany VL, Solomon SR, Edenbaum LR, Herzog WR, Gurbel PA. Mac -1 inhibitor affects certain hemostatic parameters during myocardial stunning in swine. *Pharmacology* 1996 53: 87-97.
22. Serebruany VL, Schlossberg ML, Edenbaum LR, Herzog WR, Gurbel PA. Intracoronary magnesium and diltiazem affect to a similar extent certain hemostatic factors during acute myocardial infarction in swine. *Pharmacology* 1996; 53: 224-233
23. Serebruany VL, Schlossberg ML, Edenbaum LR, Herzog WR, Gurbel PA. Hemostatic changes after early versus late intracoronary magnesium during acute myocardial infarction in swine. *J Cardiovasc Pharm* 1996; 28: 817-823.
24. Serebruany VL, Herzog WR, Edenbaum LR, Shustov AR, Gurbel PA. Changes in the haemostatic profile during magnesium deficiency in swine. *Magnesium Res* 1996; 9: 155-163.
25. Serebruany VL, Ordonez JV, Herzog WR, Rohde M, Mortensen SA, Folkers K, Gurbel PA. Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. *J Cardiovasc Pharm* 1997; 29: 16-22.
26. Serebruany VL, Herzog WR, Gurbel PA. Serial changes of the plasma prostanoids during myocardial ischemia - reperfusion in swine : Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. *Prostagland Leukotr Essen Fatty Acids* 1997; 56: 135-142.
27. Serebruany VL, Gurbel PA, Ordonez JV, Herzog WR, Rohde M, Mortensen SA, Folkers K. Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51/CD61) receptor ? *Molec Aspects Med* 1997; 18: S189-S194.
28. Herzog WR, Vogel RA, Schlossberg ML, Edenbaum LR, Scott HJ, Serebruany VL. Short-term low dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size *Intern J Cardiol* 1997; 59: 21-27.
29. Serebruany VL, Solomon SR, Herzog WR, Gurbel PA. Bolus magnesium infusion in humans is associated with predominantly unfavorable changes in platelet aggregation and certain hemostatic factors. *Pharmacol Res* 1997; 36: 17-22 .
30. Serebruany VL, Schlossberg ML, Edenbaum LR, Herzog WR, Gurbel PA. Effects of intracoronary diltiazem on certain hemostatic parameters during acute myocardial infarction in swine. *Intern J Cardiol* 1997; 61: 21-29.
31. Gurbel PA, Serebruany VL. Myths and realities of P-selectin plasma levels in patients with acute myocardial infarction. *Thromb Res* 1997; 88: 343-344.

32. Serebruany VL, Gurbel PA, Shustov AR, Dalesandro M, Gumbs SI, Grabletz BS, Bahr RD, Ohman EM, Topol EJ. Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction. *Stroke* 1998; 29: 235-238.
33. Gurbel PA, Serebruany VL. Soluble Vascular Cell Adhesion Molecule and E-selectin in patients with acute myocardial infarction treated with thrombolytic agents. *Am J Cardiol* 1998; 81: 772-775.
34. Serebruany VL, Atar D, Dalesandro MR, O'Connor CM, Gurbel PA. Changes in hemostasis after parenteral magnesium in myocardial ischemia - reperfusion : from animal studies to clinical trials. *Magnes Res* 1998 11: 37-42.
35. Serebruany VL, Bahr RD, O'Connor CM, Lowry DR, Gurbel PA, for the GUSTO-III Platelet Substudy. Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. *Cardiology* 1998; 90: 37-42.
36. Serebruany VL , Solomon SR, Herzog WR, Gurbel PA. Plasma fibronectin during myocardial ischemia - reperfusion. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. *Am J Hematol* 1998; 57: 309-314.
37. Serebruany VL, Solomon SR, Shustov AR, Herzog WH, Gurbel PA. Survival in acute myocardial infarction induced by coronary artery ligation : Prognostic relevance of certain hemostatic factors during the occlusion phase. *J Thromb Thrombolys* 1998; 5: 29-35.
38. Serebruany VL, Ordonez JV, Yurovsky VV, Gurbel, PA. The crossreactivity of human vs. swine platelet surface antigens is similar for glycoproteins Ib and IIIa, but not for IIb/IIIa complex. *J Thromb Thrombolys* 1998; 5: 37-41.
39. Gurbel PA, Serebruany VL, Shustov AR, Bahr RD, Carpo C, Ohman EM and Topol EJ, for the GUSTO III Investigators. Effects of Reteplase and Alteplase on Platelet Aggregation and Major Receptor Expression During the First 24 Hours of Acute Myocardial Infarction Treatment. The GUSTO III Platelet Study. *J Amer Coll Cardiol* 1998; 31: 1466-1473.
40. Serebruany VL, Gurbel PA, Shustov AR, Ohman EM, Topol EJ. Heterogeneity of platelet aggregation and major surface receptor expression in patients presenting with acute myocardial infarction. *Am Heart J* 1998; 136: 398-405.
41. Serebruany VL, Gurbel PA, Murugesan SR, Lowry DR, Sturm E, Svetlov SI. Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction. *Cardiology* 1998; 90: 127-130.
42. Serebruany VL , Schlossberg ML, Edenbaum LR, Herzog WR, Gurbel PA. Serial changes of soluble endothelin-1 levels during myocardial ischemia-reperfusion. Effects of magnesium, diltiazem, and a novel Mac-1 Inhibitor. *Pharmacol Res* 1998; 38: 165-172.
43. Gurbel PA, Serebruany VL, Shustov AR, Dalesandro M, Gumbs SI, Grabletz BS, Bahr RD, Ohman EM, Topol EJ. Increased baseline platelet P-selectin, and PECAM-1 as predictors of unsuccessful thrombolysis in patients with acute myocardial infarction. *Coron Artery Dis* 1998; 9: 451-456.
44. Gurbel PA, Dalesandro MR, Serebruany VL. Effects of reteplase and alteplase on soluble PECAM-1 and P-selectin in patients with acute myocardial infarction. *Thromb Haemost* 1998; 80: 725.
45. Serebruany VL, Gurbel PA. Effect of thrombolytic therapy on the plasma concentration and platelet expression of the platelet/endothelial cell adhesion molecule in patients with acute myocardial infarction. *Arterioscl Thromb Vasc Biol* 1999; 19: 153-158.

46. Serebruany VL, Gurbel PA. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P - selectin ? *Thromb Haemost* 1999; 81 : 314-316.
47. Serebruany VL, Gurbel PA. Assessment of platelet activity by measuring platelet-derived substances in plasma from patients with acute myocardial infarction: Surprising lessons from the GUSTO-III Platelet Study. *Thromb Res* 1999; 93: 149-150.
48. Svetlov SI, Moscaleva ES, Pinelis VG, Daikhin YI, Serebruany VL. Decreased intraplatelet  $Ca^{2+}$  mobilization and ATP secretion in pediatric nephrotic syndrome. *Pediatr Nephrol* 1999; 13: 205-208.
49. O'Connor CM, Gurbel PA, Serebruany VL. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. *Amer J Cardiol* 1999; 83: 1345-1349.
50. Serebruany VL, Murugesan SR, Pothula A, Semaan H, Gurbel PA. Soluble Platelet / Endothelial Cellular Adhesion Molecule-1, but not P-Selectin, nor osteonectin identify acute myocardial infarction among patients with chest pain admitted to the Emergency Department. *Cardiology* 1999; 91: 50-55.
51. Gurbel PA, Murugesan SR, Lowry DR, Serebruany VL. Plasma thromboxane and prostacyclin are linearly related and increased in patients presenting with acute myocardial infarction. *Prostagl Leukotr Essen Fatty Acids* 1999; 61: 7-11.
52. Nair GV, Gurbel PA, O'Connor CM, Gattis WM, Murugesan SR, Serebruany VL. Depression, Coronary Events, Platelet Inhibition, and Serotonin Reuptake Inhibitors. *Am J Cardiol* 1999; 84: 321-323.
53. Gurbel PA, O'Connor CM, Cummings CC, Serebruany VL. Clopidogrel : the future choice for preventing platelet activation during coronary stenting? *Pharmacol Res* 1999; 40: 107-111.
54. Serebruany VL, Yurovsky VV, Gurbel PA. Effects of novel Mac-1 inhibitor NPC 15669 on hemostatic parameters during preconditioned myocardial infarction. *Life Sci* 1999; 65: 1503-1515.
55. Murugesan SR, Gurbel PA, Serebruany VL. Storing paraformaldehyde fixed whole blood patient samples after chronic platelet glycoprotein IIb/IIIa blockade : Core laboratory considerations. *Thromb Res* 1999; 95:201-203.
56. Serebruany VL, Yurovsky VV, Gurbel PA. Mild myocardial stunning affects platelet aggregation and certain hemostatic factors in swine. *Clin Appl Thromb Hemost* 1999; 5: 236-242.
57. Serebruany VL, Murugesan SR, Pothula A, Atar D, Lowry DR, O'Connor CM, Gurbel PA. Increased soluble Platelet/Endothelial Cellular Adhesion Molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. *Eur J Heart Fail* 1999; 1: 243-249.
58. Serebruany VL, Kereiakes DJ, Dalesandro MR, Gurbel PA. Model of flow cytometer markedly affects platelet - bound P-selectin expression in patients with chest pain. Are we comparing apples with oranges ? *Thromb Res* 1999; 96:51-56.
59. McKenzie ME, Gurbel PA, Levine DJ, Serebruany VL. Clinical utility of available methods determining platelet function. *Cardiology* 1999; 92: 240-247.
60. Serebruany VL, Lowry DR, Fuzaylov SY, Levine DJ, O'Connor CM, Gurbel PA. Moderate alcohol consumption is associated with the decreased baseline platelet activity in patients presenting with acute myocardial infarction. *J Thromb Thrombolys* 2000; 9: 229-234.

61. McKenzie ME, Pothula A, Gurbel P, Fuzaylov SY, O'Connor CM, Gattis WA, Serebruany VL. Failure of Thrombin Generation Markers to Triage Patients Presenting with Chest Pain. *Cardiology* 2000; 92: 53-58.
62. Gurbel PA, Kereiakes DJ, Dalesandro MR, Bahr RD, O'Connor CM, Serebruany VL. The role of soluble and platelet-bound P-selectin in discriminating cardiac from non-cardiac chest pain at presentation in the emergency department. *Am Heart J* 2000; 139: 320-328.
63. Serebruany VL, McKenzie ME, Levine DJ, Gurbel PA. Monitoring Platelet Inhibition During Chronic Oral Platelet Glycoprotein IIb/IIIa Blockade: Are We Missing Something? *Thromb Haemost* 2000; 83: 356-357.
64. Gurbel PA, Kereiakes DJ, Atar D, Serebruany VL. Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction. *Scand Cardiovasc J* 2000; 34: 53-58.
65. Semaan HB, Gurbel PA, Anderson JL, Muhlestein JB, Carlquist JF, Horne BD, Serebruany VL. VCAM-1 and E-selectin Indicate Endothelial Activation in Patients with Documented Coronary Artery Disease. *Cardiology* 2000; 93: 7-10.
66. Nair GV, Gurbel PA, Fuzaylov SY, Davis CJ, Ohman EM, Bahr RD, Christensen RH, Serebruany VL. Combining necrosis and platelet markers for perfecting myocardial infarction rule out: How close are we? *Cardiology* 2000; 93: 50-55.
67. Gurbel PA, McKenzie ME, Serebruany VL. Initial platelet activity may predict efficacy after chronic oral glycoprotein IIb/IIIa blockade: Should we consider uniform treatment regimens? *Thromb Res* 2000; 99: 105-107.
68. Serebruany VL, Murugesan SR, D Atar, Jerome S, Semaan H, Gurbel PA. Effect of coronary thrombolysis on the plasma concentration of osteonectin (SPARC, BM40) in patients with acute myocardial infarction. *J Thromb Thrombolys* 2000; 10: 197-202.
69. Gurbel PA, Kereiakes DJ, Serebruany VL. Soluble P-selectin is not a surrogate marker for platelet P-selectin : Evidence from a multicenter chest pain study group. *J Thromb Thrombolys* 2000; 10: 15-22.
70. Pothula A, Serebruany VL, Gurbel PA, McKenzie ME, Atar D. Pathophysiology and diagnostic utility of thrombin generation in patients with coronary artery disease. *Europ J Pharm* 2000; 402: 1-10.
71. Fuzaylov SY, Serebruany VL. Amount of Paraformaldehyde for Sample Fixation Markedly Affects the Quality of Platelet Assessment by Flow Cytometry: Experience From Two Clinical Trials. *Thromb Res* 2000; 99: 643-644.
72. O'Connor CM, Gurbel PA, Serebruany VL. Depression and ischemic heart disease. *Am Heart J* 2000; 140 (4 Pt. 2) 63-69.
73. Semaan HB, Gurbel PA, Anderson JL, Muhlestein JB, Carlquist JF, Horne BD, Serebruany VL. The effect of chronic azithromycin therapy on vascular adhesion molecules in patients with coronary artery disease. *J Cardiovasc Pharm* 2000; 36: 533-537.
74. Davis CJ, Gurbel PA, Gattis WA, Fuzaylov SY, Nair GV, O'Connor CM, Serebruany VL. Hemostatic abnormalities in patients with congestive heart failure: Diagnostic significance and clinical challenge. *Intern J Cardiol* 2000; 75: 15-21.
75. Serebruany VL, Lowry DR. Take an Aspirin or Have a Drink : Antecedent Aspirin and Moderate Alcohol Consumption Similarly Affect Baseline Platelet Characteristics in Patients with Acute Myocardial Infarction. *Thromb Haemost* 2000; 84: 933-4.
76. Gurbel PA, Serebruany VL. Oral Platelet IIb/IIIa Inhibitors: From Attractive Theory to Clinical Failures. *J Thromb Thrombolys* 2000; 10: 217-220.

77. Cummings CC, McKenzie ME, Horowitz ED, Oshrine BR, Callahan KP, Gurbel PA, Serebruany VL. Platelet Function and Total Length of Intracoronary Stents: Is There a Correlation? *Thromb Res* 2001; 105-107.
78. Bell CR, Horowitz ED, Oshrine BR, Serebruany VL. Profound Inhibition of GPIIb, GPIIb/IIIa, PECAM-1, CD63, and CD107 in a Chronic Drug Addict: Selecting Controls for Platelet Flow Cytometry in the Inner City Hospital. *Thromb Res* 2001; 101: 217-218.
79. Gurbel PA, Dalesandro MR, O'Connor CM, Serebruany VL. Relation of soluble and platelet p-selectin to early outcomes in patients with acute myocardial infarction after thrombolytic therapy. *Am J Cardiol* 2001; 87: 774-777.
80. Serebruany VL, Davis CJ, Meister AF, Atar D, Whellan DJ, O'Connor CM. Biomarkers and exercise training: A possible missing link between physical activity and mortality benefit in patients with heart failure. *HeartDrug* 2001; 1: 110-24.
81. Serebruany VL, Alford AB, Meister AF, Fuzaylov SY, Gattis WA, Gurbel PA, O'Connor CM. Clinical Utility of The Platelet Function Analyzer (PFA-100<sup>®</sup>) for the AssEssment of the Platelet Status in Patients with Congestive HearT Failure (EPCOT Trial) *Thromb Res* 2001; 101: 427-433.
82. Nair GV, Davis CJ, McKenzie ME, Lowry DR, Serebruany VL. Aspirin in Patients with Coronary Artery Disease: It is Simply Irresistable? *J Thromb Thrombolys* 2001; 11: 117-26.
83. Serebruany VL, Levine DJ, Nair GV, Meister AF, Gurbel PA. Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department. *J Thromb Thrombolys* 2001; 11: 155-162.
84. Serebruany VL, Malinin AI, Bell CR, Gurbel PA. Heparin prevents Xylum Clot Signature Analyser to detect platelet inhibition with clopidogrel during coronary stenting. *Thromb Res* 2001; 102: 95-97.
85. Serebruany VL, Gurbel PA, O'Connor CM. Platelet Inhibition by Sertraline and N-Desmethylsertraline : A Possible Missing Link Between Depression, Coronary Events, and Mortality Benefits of Selective Serotonin Reuptake Inhibitors. *Pharm Res* 2001; 43: 453-62.
86. Serebruany VL, O'Connor CM, Gurbel PA. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. *Amer J Cardiol* 2001; 87: 1398-1400.
87. Callahan KP, Malinin AI, Gurbel PA, Alexander JH, Granger CB, Serebruany VL. Platelet Function and Fibrinolytic Agents: Two Sides of a Coin? *Cardiology* 2001; 95: 55-60.
88. Serebruany VL, Cummings CC, Malinin AI, Steinhubl SR, Gurbel PA. Uniform platelet activation exists before coronary stent implantation despite aspirin therapy. *Am Heart J*, 2001; 142: 611-616.
89. Serebruany VL, Steinhubl SR, Malinin AI, Kallahan KP, Gurbel PA. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. *Atherosclerosis*, 2001; 239: 259-261.
90. Callahan PA, Malinin AI, Atar D, Serebruany VL. Platelet Activation as a Universal Trigger in the Pathogenesis of Acute Coronary Events After Cocaine Abuse. *Swiss Med Wkly*, 2001; 131: 487-9.
91. Malinin AI, Callahan KP, Serebruany VL. Paradoxical Activation of Major Platelet Receptors in the Methadone-Maintained Patients After Single Pill of Aspirin. *Thromb Res* 2001; 104: 297-9.
92. Callllahan KP, Malinin AI, Gurbel PA, Alexander JH, Granger CB, Atar D, Serebruany VL. Platelets and Thrombolysis: Cooperation or Contrariety? *Heart Drug* 2001; 1:281-290.
93. Gurbel PA, Serebruany VL. Adhesion molecules, platelet activation, and cardiovascular risk. Editorial. *Am Heart J* 2002; 143-196-8.

94. Serebruany VL, McKenzie ME, Meister AF, Fuzaylov SY, Gurbel PA, Atar D, Gattis WA, O'Connor CM: Failure of Platelet Parameters and Biomarkers to Correlate Platelet Function to Severity and Etiology of Heart Failure in Patients Enrolled in the EPCOT Trial. With special reference to the Hemodyne Hemostatic Analyzer. *Pathophys Hemost Thromb* 2002;32:8-15.
95. Malinin AI, Atar D, Serebruany VL. Selective Serotonin Reuptake Inhibitors: Future Treatment of Vascular Disease? *HeartDrug* 2002; 1:332-340.
96. McKenzie ME, Bell CR, Horowitz ED, Oshrine BR, Atar D, Serebruany VL. Effects of in vitro exposure of alcohol on surface receptor expression of human platelets. *Clyn Physiol Funct Imaging* 2002; 22: 153-156.
97. Gurbel PA, Malinin AI, Callahan KP, Serebruany VL, O'Connor CM. Effect of Loading With Clopidogrel at the Time of Coronary Stenting on Platelet Aggregation and Glycoprotein IIb/IIIa Expression and Platelet-Leucocyte Aggregate Formation. *Am J Cardiol* 2002; 90:14-17.
98. Gurbel PA, Gattis WA, Fuzailov Syu, Gaulden L, Hasselblad V, Serebruany VL, O'Connor CM. Evaluation of platelets in heart failure: is platelet activity related to etiology, class or clinical outcomes? *Am Heart J* 2002; 143: 1068-1075.
99. Malinin AI, Eisert RM, Atar D, Barkagan ZS and Serebruany VL. Aggrenox<sup>®</sup> (Extended Release Dipyridamole And Low Dose Aspirin in Combination): Protecting Platelets From Excessive Activation in Patients With Vascular Events. *HeartDrug* 2002; 2: 93-104.
100. Bahr RD, Gurbel PA, Malinin AI, Wentz C, Christenson RH, Roe MT, Gibler WB, Kitt MM, Ohman EM, Serebruany VL for the EARLY Trial Investigators. Relation of Platelet Activation and Myocardial Ischemia Biomarkers Dependent to Type of Chest Pain (Abrupt Onset – vs – Intermittent) in Patients with Angina Pectoris or Non -Q Wave Acute Myocardial Infarction. *Am J Cardiol* 2002; 90:310-312.
101. Gurbel PA, Malinin AI, Callahan KP, Serebruany VL, O'Connor CM. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation, glycoprotein IIb/IIIa expression, and platelet-leukocyte aggregate formation. *Am J Cardiol* 2002; 90: 312-315
102. Serebruany VL, McKenzie ME, Meister AF, Fuzaylov SYu, Gurbel PA, Gattis WA, O'Connor CM. Whole Blood Impedance Aggregometry for the Assessment of the Platelet Function in Patients with Congestive Heart Failure (EPCOT Trial). *Europ J Heart Fail* 2002;4:461-466.
103. Gurbel PA, Callahan KP, Malinin AI, Serebruany VL, Gillis J. Could stent design affect platelet activation? Results of the Platelet Activation in Stenting (PAST) trial. *J Invas Cardiol* 2002; 14: 584-9.
104. Sane DC, McKee, SA, Malinin AI, Serebruany VL. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. *Am J Cardiol* 2002; 90; 893-894.
105. McKenzie ME, Bell CR, Horowitz ED, Oshrine BR, Malinin AI, Atar D, Serebruany VL. Aspirin inhibits surface GPIIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets. *Blood Coag Fibrinol* 2003; 14: 1-5.
106. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and Extent of Platelet Inhibition by Clopidogrel Loading in Patients Undergoing Elective Coronary Stenting – The PRONTO (Plavix Reduction of New Thrombus Occurrence) Trial. *Am Heart J* 2003; 145: 239-247.

107. Malinin AI, Atar D, Callahan KP, McKenzie ME, Serebruany VL. Effects of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. *Europ J Pharm* 2003; 462: 139-143.
108. Serebruany VL. Antiplatelet properties of sertraline and survival benefits in patients with depression after acute coronary events. *Acute Coron Syndr* 2003; 5: 76-80.
109. Serebruany VL, Malinin AI, Callahan KP, Binbreck AS, van de Werf F, Alexander JH, Granger CB, Gurbel PA. Effect of Tenecteplase versus Alteplase on Platelets in Patients During the First Three Hours of Treatment of Acute Myocardial infarction (The ASSENT-2 Platelet Substudy). *Am Heart J* 2003; 245: 636-642.
110. Malinin AI, O'Connor CM, Dzhanashvili AI, Sane DC, Serebruany VL. Platelet Activation in Patients with Congestive Heart Failure: Do We Have Enough Evidence to Consider Clopidogrel? *Am Heart J* 2003;145:397-403.
111. Serebruany VL, Malinin AI, Sane DC. "Rapid platelet inhibition after a single pill Aggrenox<sup>®</sup>: Challenging a conventional full-dose aspirin antiplatelet advantage?" *Am J Hematol* 2003;72:280-281.
112. Serebruany V.L., Steinhubl SR, Hennekens CH. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested (Editorial). *Circulation* 2003;107:1568-1569.
113. Serebruany VL, Glassman AH, Malinin AI, Atar D, Sane DC, Oshrine BR, Ferguson JJ, O'Connor CM. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. *Europ J Heart Fail* 2003; 5: 517-521.
114. Serebruany VL, Malinin AI, O'Connor CM, Gurbel PA. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease. For the Roxifiban Oral Compound Kynetics Evaluation Trial-I (The ROCKET-I Platelet Substudy). *Amer Heart J* 2003; 146: 91-98.
115. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CH, Musselman DT, Krishnan RR, van Zyl LT, Finkel MS, Harrison W, Califf RM, O'Connor CM for the SADHART Study Group. Platelet/Endothelial Biomarkers in Patients Treated with Selective Serotonin Reuptake Inhibitor for Depression after Acute Coronary Events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. *Circulation*, 2003; 108:939-944.
116. Gurbel PA, Galbut B, Bliden KP, Bahr RD, Roe MT, Serebruany VL, Gibler WB, Christenson RH, Ohman EM. Effect of Eptifibatide for acute coronary syndromes: Rapid versus late administration-therapeutic yield on Patients (The EARLY Platelet Substudy). *J Thromb Thrombolys* 2002; 14: 213-219.
117. Serebruany VL, Glassman AH, Malinin AI, Sane DC, Finkel MS, Krishnan RR, Lekht V, O'Connor CM. Platelet/Endothelial activation in depressed patients after acute myocardial infarction and unstable angina: Evidence from clinical trials. *Blood Coag Fibrin* 2003; 14: 1-5
118. Saw J, Steinhubl S, Berger P, Kereiakes D, Serebruany V, Brennan D, Topol E. Lack of clinical evidence of clopidogrel – atorvastatin interaction in a randomized, controlled clinical trial. *Circulation* 2003; 108: 921-924.
119. Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, Tanguay J-F, Steinhubl SR, O'Connor CM. Effect of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure:



- The Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. *Am Heart J* 2003; 146:713-720.
120. Serebruany VL, Malinin AI, Sane DC. Risk of Bleeding Complications With Antiplatelet Agents: A Meta-Analysis of 338,191 Patients Enrolled in 50 Randomized Controlled Trials. *Am J Hemat* 2004; 75: 40-47.
  121. Joynt KE, Gattis WA, Hasselblad V, Fuzaylov SA, Serebruany VL, Gurbel PA, Gaulden LH, Felker GM, Whellan DJ, O'Connor CM. Effect of angiotensin receptor inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. *Am J Cardiol* 2004; 93: 783-785.
  122. Serebruany VL, Malinin AI, Lowry DR, Sane DC, Webb RL, Gottlieb SO, Hennekens CH. Platelet Inhibition by Valsartan and Valeryl 4-hydroxy Valsartan: A Possible Missing Link to Explain Benefits of Angiotensin II Receptor Blockers in Patients After Acute Vascular Events. *J Cardiovasc Pharm* 2004; 43: 677-684.
  123. Malinin A, Spergling M, Muhlestein B, Michelson A, Steinhubl S, Serebruany V. Assessing Aspirin Responsiveness in Subjects with Multiple Risk Factors for Vascular Disease with the Rapid Platelet Function Analyzer Blood Coag Fibrinol 2004; 15: 1-7.
  124. Malinin AI, Oshrine BR, Serebruany VL. Should We Consider Selective Serotonin Reuptake Inhibitors for Treating Wound Healing? *Medical Hypothesis* 2004; 63: 103-109.
  125. Serebruany VL, Oshrine BR, Malinin AI, Sane DC, Takserman A, Atar D, Hennekens CH. Lack of the uniformed platelet activation in patients after ischemic stroke: Does aspirin matters? *Thromb Research* 2004; 113: 197-204.
  126. Serebruany VL, Hanley DF, Atar D, Ferguson JJ. Non - compliance in antiplatelet trials: The AGATE trial perspective. *Stroke* 2004; 35: 143.
  127. Serebruany VL, Malinin AI, Sane DC, Takserman A, Atar D, and Hennekens CH. Magnitude and time course of platelet inhibition with Aggrenox and aspirin in patients after ischemic stroke. The AGgrenox versus Aspirin Therapy Evaluation (AGATE) Trial. *Europ J Pharm* 2004; 499:315-324.

## **B. Accepted:**

1. Serebruany VL, Suckow RF, Cooper TB, Glassman AH, Malinin AI, Krishnan RR, Lekht V, Harrison W, Clary CM, O'Connor CM for the SADHART trial. Release of Platelet/Endothelial Biomarkers Negatively Correlates with the Plasma Levels of Sertraline and N-Desmethylertraline in Depressed Patients After Acute Coronary Syndromes Treated with Selective Serotonin Reuptake Inhibitor. *Am J Psych*
2. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane D, Tanguay JF, Steinhubl SR, Berger PB, O'Connor CM, Hennekens CH. Absence of Interaction Between Atorvastatin and Clopidogrel in Prospective Data: The Interaction of Atorvastatin and Clopidogrel (INTERACTION Study). *Arch Int Med*
3. Serebruany VL. Reteplase plus abciximab improves non-fatal outcomes, but not overall survival in people with diabetes and acute ST-elevation myocardial infarction (Commentary). *Evidence Based Healthcare*.
4. Serebruany VL, Steinhubl SR, Berger PB, Bhatt DL, Michelson AD, Topol EJ. Variability in Platelet Responsiveness to Clopidogrel Among 544 Individuals. *JACC*

### C. Submitted:

1. Malinin AI, Oshrine BR, Sane DC, O'Connor CM, Serebruany VL. Does Heart Failure Etiology, NYHA Class, or Ejection Fraction Affect the Ability of Clopidogrel to Inhibit Heightened Platelet Activity? Blood Coag Fibrinol
2. Serebruany VL, Oshrine BR, Malinin AI, Michelson AD, Jerguson JJ. Noncompliance in Clinical Trials (Editorial). Am Heart J
3. Serebruany VL, Malinin AI, Berger PB, Steinhubl SR, Baggish JS, Bhatt DL, Topol EJ. The Risk of Bleeding Complications After Different Doses of Aspirin: A *post-hoc* Analysis of 192,036 Patients Enrolled in 31 Randomized Controlled Trials. Ann J Med
4. Kotzailias N, Dukic A, Serebruany VL, Jilma B. Safety and Efficacy of Co-administration of the selective Serotonin Reuptake Inhibitor Paroxetine and Aspirin in Male Smokers -a prospective randomized placebo controlled study. J Thromb Haemost
5. Oshrine BR, Malinin AI, Pokov AN, Dragan A, Serebruany VL. Changes of pH are critical for accurate fluorometric measurements of dipyridamole levels in biological fluids. Clin Pharmacokin
6. Serebruany VL, Pokov AN, Malinin AI, Sane DC, Tanguay J-F, Bhatt D, and Hennekens CH. Effect of valsartan on platelets in patients with mild to moderate hypertension: The Valsartan Inhibits Platelets (VIP) Trial Circulation

### Abstracts :

1. Serebruany VL. Immunological profile in children with acute leukemia, undergoing BCG-vaccine treatment. Medical student's conference. Erevan, (Armenia) 1982; 178-179.
2. Manin VM, Rumyantzev AG, Serebruany VL. Rehabilitation programs for children with acute lymphoblastic leukemia. USSR Hematology Symposium. Orel, 1982; 108-109.
3. Axelrod VG, Serebruany VL. Efficiency of "Pulmarka"® (Drager AG, Germany) in the treatment of respiratory distress syndrome in premature newborns. Russian Perinatology Symposium. Moscow, 1983; 7-8.
4. Axelrod VG, Serebruany VL. Transcutaneous PaO<sub>2</sub> detection in the newborns. Medical Research Fellow's Conference. Moscow, 1984; 3-4.
5. Vichireva ZN, Serebruany VL. Peroxydation of lipids during newborn sepsis. USSR Hematology Symposium. Orel, 1984, 38-39.
6. Gavrusev VV, Axelrod VG, Serebruany VL. Treatment of hypoxemia in the newborns with the continuous negative air pressure. XII Pediatric Congress of Estonia. Tallinn, 1985; 1 : 105-106.
7. Stuklov VI, Medvedev MV, Serebruany VL. Role of echography in the detection of congenital urinary tract malformations in fetus. III USSR Congress on Obstetrics & Gynecology. Alma-Ata, Kazakhstan 1985; 201-202.

8. Serebruany VL, Barkagan LZ. Hemostasis in children with the nephrotic syndrome. *Inter J Pediatric Nephrol*, 1987; 8 : 112.
9. Barkagan LZ, Serebruany VL, Anmut NY. Platelet aggregation and von Willebrand factor in children with immune nephropathies. *Ibid*, p.125.
10. Serebruany VL, Ignatova MS, Degtyareva EM. Thrombotic complications in children with minimal change nephrotic syndrome, USSR Conference on Thrombosis & Hemostasis, Moscow, 1987; 83-84.
11. Svetlov SI, Serebruany VL. Plasma platelet activating factor levels in children undergone chronic hemodialysis. *Ibid*, 98-99.
12. Serebruany VL, Medvedev MV, Davidov AI. Antenatal ultrasound diagnosis of kidneys and urinary tract malformations. *Union Symposium on Perinatology*. Moscow, 1987, 105-107.
13. Medvedev MV, Serebruany VL, Axelrod VG. Estimation of heart ventricles function in fetus and in the newborn, using echocardiography. *Ibid*, 108-109.
14. Veltischev YE, Serebruany VL, Svetlov SI, Moskaleva ES. Platelet function in children with the chronic renal failure, estimated by platelet aggregation in response to different inductors. *V<sup>th</sup> European Symposium on Pediatric Nephrology* . Warsaw (Poland) 1988; 15.
15. Kopileva OD, Degtyareva EM, Serebruany VL. Analysis of clinical outcomes in children with Henoch - Schönlein nephritis. *VII Russian Nephrology Congress*. Novosibirsk, 1988; 34-35.
16. Serebruany VL. Hemostatic abnormalities due to heparin treatment in children with nephrotic syndrome. *Ibid*, 66-67.
17. Veltischev YE, Svetlov SI, Serebruany VL. Platelet response to the platelet-activating factor during the nephrotic syndrome in children, *XXI European Congress of Pediatric Nephrology*, *Pediatr Nephrol* 1989; 3 : 147.
18. Serebruany VL, Degtyareva EM. Heparin treatment in patients with mesangiocapillary glomerulonephritis. *Russian Hematology Symposium*. 1989; 101-104.
19. Veltischev YE, Svetlov SI, Serebruany VL, Pinelis VG. Platelet-activating factor, thromboxane B2 and platelet aggregation in children with the nephrotic syndrome. *VIII World Congress on Pediatric Nephrology*. *Pediatr Nephrol* 1989; 4 : C171.
20. Serebruany VL, Kubatiev AA. Plasma prostacyclin level in children with the nephrotic syndrome. *Ibid*, C170.
21. Serebruany VL, Kubatiev AA, Smirnov IE. Changes of plasma prostacycline in children with the nephrotic syndrome during the isolated prednisolone therapy. *III International Congress on Prostaglandins*. Washington, D.C., 1991; # 372
22. McLean RH, Serebruany VL, Delaney N, Lin X-Y, Wang S-R, Bias W H. Rare slow C4B allele in Taiwanese lupus patients. *XI International Histocompatibility Workshop*. Yokohama, (Japan) 1991.
23. Oei AS, Herzog WR, Bartlett ST, Evans D, Serebruany VL. Platelet aggregation in patients with renal transplantation. *International research conference, UMB, Baltimore*. 1993; 38.
24. Khan ZS, Serebruany VL, Schlossberg ML, Herzog WR. Effect of coenzyme Q10 on myocardial stunning in swine. *Ibid*; 24.
25. Herzog WR, Atar D, Mortensen SA, Schlossberg ML, Serebruany VL. Effect of Coenzyme Q10 supplementation on platelet aggregability in swine. *X European Symposium "Q10 in clinical practice"*. Stockholm, 1993.
26. Herzog WR, Rinder MR, Atar D, Serebruany VL. Platelet aggregability decreases after magnesium infusion in swine with initial normal serum magnesium level. *American Heart Association, Anaheim*, 1993.

27. Gurbel PA, Komjathy SF, Collins ME, Scott HJ, Schlossberg ML, Serebruany VL, Herzog WR. Both coronary and systemic platelet aggregation are enhanced following reperfusion after brief ischemia. *Eur Heart J* 1994; 15:106.
28. Gurbel PA, Serebruany VL, Komjathy SF, Collins ME, Schlossberg ML, Herzog WR. The effect of myocardial ischemia/reperfusion on regional and systemic platelet function. *Clin Res* 1994; 42:163A.
29. Gurbel PA, Komjathy SF, Collins ME, Schlossberg ML, Serebruany VL, Herzog WR. Intravenous administration of NPC15669, a leumedin, markedly reduces myocardial stunning. *Clin Res* 1994; 42:163A.
30. Herzog WR, Atar D, Rinder MR, Gurbel PA, Serebruany VL. Magnesium infusion decreases platelet aggregability in swine. *J Am Coll Cardiol* 1994; 23:31A.
31. Schlossberg ML, Herzog WR, Rinder MR, Serebruany VL, Gurbel PA, Schneider AI, Edgeworth N, Pou S, Rosen GM. Intracoronary nitroprusside delivery ameliorates myocardial stunning with systemic effects. *Clin Res* 1994; 42:163.
32. Schlossberg ML, Herzog WR, Rinder MR, Serebruany VL, Gurbel PA. Intracoronary Nitroprusside delivery ameliorates myocardial stunning with minimal systemic effects. American Federation for Clinical Research Meeting, Baltimore. 1994. 715-3:87A.
33. Herzog WR, Mortensen SA, Serebruany VL. Dose dependent effects of Coenzyme Q10 on platelet aggregation in swine. *Ibid*, 94A.
34. Gurbel PA, Serebruany VL, Komjathy SF, Collins ME, Scott H, Schlossberg ML, Herzog WR. Intravenous NPA 15669, a leumedin, selectively inhibits regional platelet hyperaggregability that develops during myocardial ischemia - reperfusion. *Circulation* 1994; 90:I-373.
35. Herzog WR, Gurbel PA, Cowfer JP, Mann DJ, Serebruany VL. Intracoronary MgSO<sub>4</sub> during reperfusion limits infarct size in a swine model. *Magnes Res* 1994; 7:67.
36. Serebruany VL, Schlossberg ML, Gurbel PA, Vogel RA, Herzog WR. Effect of NPC 15669 on Myocardial Stunning and Infarction Size in Swine. *J Am Coll Cardiol* 1995; 931-110:116A.
37. Serebruany VL, Solomon SR, Gurbel PA, Herzog WR. Mg-deficiency in swine is associated with hemostatic disorder. *Eur Heart J* 1995; 16:137.
38. Mortensen SA, Cestatello JA, Serebruany VL, Herzog WR, Rohde M, Lingle DM, Whitman GJR. Coenzyme Q10 therapy: A cardiometabolic approach which favorably modulates ischemia and thus may prevent failure. International Meeting on Heart Failure. Amsterdam, 1995.
39. Serebruany VL, Herzog WR, Gurbel PA. Bolus magnesium infusion unfavorably affects platelet aggregability and certain hemostatic factors in human volunteers. *Eur Heart J* 1996; 17: 77.
40. Serebruany VL, Shustov AR, Gurbel PA, Herzog WR. Effects of Mac-1 inhibitor on hemostasis during myocardial stunning in swine. *J Am Coll Cardiol* 1996; 27: 2A.
41. Serebruany VL, Herzog WR, Gurbel PA. Mild myocardial stunning affects platelet aggregation and hemostasis in swine. *FASEB J*. 1996; 10:A34.
42. Serebruany VL, Herzog WR, Gurbel PA. Bolus magnesium infusion in humans is associated with predominantly unfavorable changes in platelet aggregation and certain hemostatic factors. *J Am Coll Cardiol* 1997; 29: 134A.
43. Serebruany VL, Rohde M, Mortensen SA, Folkers K, Morgan AW, Gurbel PA. Dietary Coenzyme Q10 Supplementation inhibits human platelet vitronectin (CD51/CD61) receptor expression. *Proc Soc Exper Biol Med* 1997; 215: 109.

44. Gurbel PA, Serebruany VL, Bahr RD, Shustov AR, Ohman EM. Effects of alteplase and reteplase on platelet aggregation and major surface antigen receptor expression during the first 24 hours in patients with acute myocardial infarction. The GUSTO-III platelet study. *Circulation* 1997; 96: I 261.
45. Serebruany VL, Bahr RD, Shustov AR, Carpo C, Gurbel PA. Marked heterogeneity of platelet aggregation and surface receptor expression in patients presenting with acute myocardial infarction. *Circulation* 1997; 96: I 262.
46. Gurbel PA, Serebruany VL, Dalesandro MR, O'Connor CM. Course of platelet and soluble P-Selectin in patients with acute myocardial infarction after thrombolytic therapy: New marker of successful reperfusion ? The XIIIth World Congress of Cardiology. Rio de Janeiro, (Brazil), 1998.
47. Serebruany, VL, O'Connor CM, Gurbel PA. Effect of coronary thrombolysis on the platelet expression and plasma concentration of the Platelet/Endothelial Cell Adhesion Molecule - 1 (PECAM-1, CD31) in patients with acute myocardial infarction. *Ibid*, 1998.
48. Serebruany VL, Murugesan SR, Pothula A, Semaan H, Jerome S, Gurbel PA. Effect of coronary thrombolysis on the plasma concentration of osteonectin (SPARC, BM40) in patients with acute myocardial infarction. *J Amer Coll Cardiol* 1999; 33: 382A.
49. O'Connor CM, Gurbel PA, Serebruany VL. Soluble and surface-bound P-selectin reveal heightened platelet activity in patients with decompensated heart failure : Is aspirin Therapy Enough? *J Amer Coll Cardiol* 1999; 33: 206A.
50. Serebruany VL, Murugesan SR, Gurbel PA. Storing paraformaldehyde fixed whole blood patient samples after chronic platelet glycoprotein IIb/IIIa blockade : Core laboratory considerations. XVII Congress of the International Society on Thrombosis and Haemostasis, Washington, D.C. *Thromb Haemost* 1999; 82: Suppl: 637.
51. Gurbel PA, Kereiakes DJ, Dalesandro MR, Serebruany VL. The role of platelet and soluble P-selectin in discriminating cardiac from non-cardiac chest pain at presentation to the Emergency Department. *Idid*; 447-448.
52. Serebruany VL, Kereiakes DJ, Atar D, Gurbel PA. Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction. *Ibid*; 455-456.
53. Gurbel PA, Kereiakes DJ, Atar D, Serebruany VL. Soluble and platelet P-selectin in patients with chest pain : Evidence for endothelial origin. *Ibid*; 628.
54. Serebruany VL, Murugesan SR, Atar D, O'Connor CM, Gattis WA, Gurbel PA. Increased soluble PECAM-1 and osteonectin levels in patients with severe congestive heart failure. *Idid*; 657.
55. Serebruany VL, Murugesan SR, Kereiakes DJ, Dalesandro MR, Gurbel PA. Flow cytometer model markedly affects the measurements of platelet-bound P-selectin in patients presented with chest pain. *Ibid*; 637.
56. Serebruany VL, Murugesan SR, Kereiakes DJ, Dalesandro MR, Gurbel PA. Flow cytometer model markedly affects the measurements of platelet P-selectin in patients with chest pain. XXI Congress of the European Society of Cardiology. Barselona, Spain. *Europ Hear J* 1999; 20:190.
57. Gurbel PA, O'Connor CM, Gattis WA, Serebruany VL. Soluble and surface-bound P-selectin reveal heightened platelet activity in patients with decompensated heart failure : Is aspirin therapy enough? *Ibid*: 198.

58. Serebruany VL, Kereiakes DJ, Atar D, Gurbel PA. Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction. *Ibid*: 120.
59. Gurbel PA, Kereiakes DJ, Atar D, Serebruany VL. Soluble P-selectin in patients presenting with chest pain : Evidence for endothelial origin. *Ibid*:420.
60. Serebruany VL, Murugesan SR, Atar D, O'Connor CM, Gattis WA, Gurbel PA. Increased soluble PECAM-1 and osteonectin levels in patients with severe congestive heart failure. *Ibid*; 199.
61. Serebruany VL, Gurbel PA, O'Connor CM. Platelet Inhibition by Sertraline and N-Desmethylsertraline: A Possible Missing Link to Explain Benefits of Selective Serotonin Reuptake Inhibitors in Depressed Patients after Acute Coronary Events. *J Am Coll Cardiol* 2000; 35: (Suppl.A 282).
62. Serebruany VL, Gurbel PA, O'Connor CM. Platelet Inhibition by Sertraline and N-Desmethylsertraline: A Possible Missing Link to Explain Benefits of Selective Serotonin Reuptake Inhibitors in Depressed Patients after Acute Coronary Events. *Europ Heart J* 2000; 21 Suppl.: 179.
63. Serebruany VL, Fuzaylov SY, Gattis WA, Gurbel PA, O'Connor CM. Utility of cartridge-based analyzers in the Evaluation of Platelet function in patients with Congestive heart failure Trial (EPCOT). *Ibid*; p.297.
64. Semaan HB, Gurbel PA, Muhlestein JB, Carlquist JF, Horne BD, Anderson JL, Serebruany VL. The effect of chronic azithromycin therapy on soluble endothelial derived adhesion molecules in patients with coronary artery disease. *AHA-2000*.
65. Gurbel PA, Cummings CC, Alford AB, Meister AF, Serebruany VL. Onset and Extent of Platelet Inhibition by Loading Dose Clopidogrel in Patients Undergoing Elective Coronary Stenting – The PRONTO (Plavix for Reduction of New Thrombus Occurrence) Trial. *JACC*; 2001 37: 32.
66. Serebruany VL, O'Connor CM, Gurbel PA. Selective Serotonin Reuptake Inhibitors Affect Platelets in Patients Undergoing Coronary Stenting. *JACC*; 2001 37 : 299-300.
67. McKenzie ME, Bell CR, Horowitz ED, Oshrine BR, Serebruany VL. Aspirin Inhibits GPIIb/IIIa, P-selectin, CD63, and CD107a Surface Receptor Expression on Human Platelets. *JACC*; 2001 37: 224
68. Serebruany VL, O'Connor CM, Gurbel PA. Selective Serotonin Reuptake Inhibitors Affect Platelets in Patients Undergoing Coronary Stenting. *Thromb Haemost*; 2001 86 : 195.
69. Malinin AI, McKenzie ME, Horowitz ED, Oshrine BR, Serebruany VL. Aspirin Inhibits GPIIb/IIIa, P-selectin, CD63, and CD107a Surface Receptor Expression on Human Platelets. *Thromb Haemost*; 2001 86: 208.
70. Serebruany VL, Malinin AI, Bell CR, Gurbel PA. Heparin prevents Xylum Clot Signature Analyser to detect platelet inhibition with clopidogrel during coronary stenting. *Thromb Haemost*; 86: 223.
71. Gurbel PA, Cummings CC, Alford AB, Meister AF, Serebruany VL. Onset and Extent of Platelet Inhibition by Loading Dose Clopidogrel in Patients Undergoing Elective Coronary Stenting – The PRONTO (Plavix for Reduction of New Thrombus Occurrence) Trial. *Europ Heart J*; 2001; 194.
72. Serebruany VL, Malinin AI, Callahan KP, Binbreck AS, van de Werf F, Alexander JH, Granger CB, Gurbel PA. Effect of Tenecteplase versus Alteplase on Platelets in Patients During the First Three Hours of Treatment of Acute Myocardial infarction (The ASSENT-2 Platelet Substudy). *Circulation* 2001; 104: 539

73. Gurbel PA, Malinin AI, Callahan KP, Serebruany VL. Loading With 300mg Clopidogrel at the Time of Coronary Intervention Results in Decreased Platelet Aggregation, GPIIb/IIIa Expression and Activation of Platelet-Leukocyte Aggregates. *Circulation* 2001; 104:707
74. Serebruany VL, Glassman AH, Malinin AI, Krishnan RR, Finkel MM, Nemeroff C, Gurbel PA, Clary C, Harrison W, O'Connor CM. Effects of Zolofit® on Platelet/Endothelial Biomarkers in Depressed Patients After Acute Coronary Events: Sertraline Anti-Depressant Heart Attack Randomized Trial (SADHART Platelet Substudy). *JACC* 2002; 39 (supplement A): 286A, and WCC-2002, Sydney, 2002, and European Society of Cardiology Meeting (Berlin, 2002).
75. Gurbel PA, Malinin AI, Callahan KP, Buczkowski MJ, Serebruany VL. How Rapidly and Durably Are Platelets Inhibited by a 300 mg Clopidogrel Loading Dose Given at the Time of Intervention Compared to Loading Before Intervention? *JACC* 2002; 39 (supplement A): 286A: 52A
76. Malinin AI, Callahan KP, McKenzie ME, Serebruany VL. Effect of a Single Dose of Aspirin (325 mg) on Platelets in Human Volunteers With Multiple Risk Factors for Coronary Artery Disease. *JACC* 2002; 39 (supplement A): 260A.
77. Serebruany VL, Steinhubl SR, Malinin AI, Callahan KP, Gurbel PA. Statins in General and Atorvastatin in Particular Do Not Affect Platelet Inhibition with Clopidogrel During Coronary Stenting. WCC-2002, Sydney, ESC Berlin 2002, and ACC 2003, Chicago
78. Bahr RD, Gurbel PA, Malinin AI, Christenson RH, Roe MT, Gibler WB, Kitt M, EM Ohman, Serebruany VL for the EARLY Trial Investigators Correlation of Platelet Activation and Myocardial Ischemia Biomarkers Dependent on a Chest Pain Onset: Does Prodroma Matters? European Congress of Cardiology, AHA, 2002
79. Serebruany VL, Glassman AH, Malinin AI, Krishnan RR, Gurbel PA, O'Connor CM. Platelet/Endothelial Activation in Depressed Patients after Acute Myocardial Infarction and Unstable Angina: Evidence from Clinical Trials. *Ibid*
80. Serebruany VL, Glassman AH, Malinin AI, Sane DC, O'Connor CM. Selective Serotonin Reuptake Inhibitors Yield Additional Antiplatelet Benefit in Patients with Heart Failure Treated with Antecedent Aspirin. *Ibid*, and AHA 2002
81. Serebruany VL, Malinin AI, Sane DC. The risk of bleeding complications with antiplatelet agents: a meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. AHA 2002 and Amer Neurol Assoc Meeting, New York 2002; AHA2002; ESC2003
82. Serebruany VL, Malinin AI, Sane DC. Rapid platelet inhibition after a single pill of Aggrenox®: Challenging a conventional full-dose aspirin antiplatelet advantage? ANA 2002
83. Serebruany VL, Malinin AI, O'Connor CM, Gurbel PA. Effect of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease (The ROCKET-I Platelet Study). Berlin 2002, and AHA 2002
84. Serebruany VL, Malinin AI, Lowry DR, Gottlieb SO, Sane DC, Hennekens CH. Platelet Inhibition by Valsartan and Valeryl 4-hydroxy Valsartan: A Possible Missing Link to Explain Benefits of Angiotensin II Receptor Blockers in Patients After Acute Vascular Events. ACC – 2003; ISTH XIX congress, Birmingham, UK; and ESC (Vienna, 2003)
85. Serebruany VL, Malinin AI, Jerome SE, Morgan AW, Lowry DR, Sane DC, O'Connor CM. Effects of clopidogrel-aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure. For the PLavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) Trial ACC-2003.

86. Gurbel PA, Gattis WA, Fuzaylov SF, Gaulden L, Hasselblad V, Serebruany VL, O'Connor CM. Evaluation of Platelets in Heart Failure: Is Platelet Activity Related to Etiology, Functional Class, or Clinical Outcomes? ACC-2003.
87. Gurbel PA, Bahr RD, Roe MT, Serbruany VL, Malinin AI, Gibler WB, Ohman EM. EARLY Platelet Substudy. ACC-2003
88. Serebruany VL, Malinin AI, Jerome SD, Morgan AW, Lowry DR, Sane DC, Steinhubl SR, Tanguay J-F, O'Connor CM. Effect of Clopidogrel and Aspirin Combination versus Aspirin Alone on Platelet Aggregation and Major Receptor Expression in Patients with Heart Failure. The Plavix Use for Treatment Of CHF (PLUTO-CHF trial). Ibid.
89. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane D, Tanguay JF, Steinhubl SR, Berger PB, O'Connor CM, Hennekens CH. Absence of Interaction Between Atorvastatin and Clopidogrel in Prospective Data: The Interaction of Atorvastatin and Clopidogrel (INTERACTION Study). ESC (Vienna, 2003); TCT (Washington, DC, 2003); AHA (Orlando, 2003).
90. Serebruany VL, Suckow RF, Cooper TB, Glassman AH, Malinin AI, Krishnan RR, Lekht V, Harrison W, Clary CM, O'Connor CM for the SADHART trial. Release of Platelet/Endothelial Biomarkers Negatively Correlates with the Plasma Levels of Sertraline and N-Desmethylertraline in Depressed Patients After Acute Coronary Syndromes Treated with Selective Serotonin Reuptake Inhibitor. AHA (Orlando, 2003)
91. Saw J, Steinhubl S, Berger P, Kereiakes D, Serebruany V, Brennan D, Topol E. Lack of clinical evidence of clopidogrel – atorvastatin interaction in a randomized, controlled clinical trial. Ibid
92. Serebruany VL, Malinin AI, Sane DC, Takserman A, Atar D, and Hennekens CH. Magnitude and time course of platelet inhibition with Aggrenox and aspirin in patients after ischemic stroke. The AGgrenox versus Aspirin Therapy Evaluation (AGATE) Trial. Ibid, and 29<sup>th</sup> Stroke Congress (San Diego, 2004).
93. Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V. Detection of aspirin resistance in subjects with multiple risk factors for cardiovascular disease. Am Coll Cardiol 2004.
94. Serebruany VL, Hanley D. Lack of phasic rebounds with Aggrenox in post-stroke patients: The core laboratory experience from the recent antiplatelet trials (EuroStroke-2004, Mannheim, Germany; and 5<sup>th</sup> World Stroke Congress, Vancouver, Canada, 2004).
95. Serebruany VL, Malinin AI, Sane DC. The in vitro effects of dipyridamole on platelet activation, annexin-V binding, and thrombin generation: Overcoming aspirin resistance with Aggrenox? (EuroStroke-2004, Mannheim, Germany; and 5<sup>th</sup> World Stroke Congress, Vancouver, Canada, 2004).
96. Serebruany VL, Steinhubl SR, Berger PB, Bhatt DL, Michelson AD, Topol EJ. Variability in Platelet Responsiveness to Clopidogrel Among 544 Individuals. Europ Congress of Cardiology, Munich, Germany, 2004, TCT, Washington, DC, 2004, Amer Heart Assoc, New Orleans, 2004.
97. Serebruany VL, Oshrine BR, Malinin AI, Sane DC, Takserman A, Atar D, Hennekens CH. Lack of the uniformed platelet activation in patients after ischemic stroke: Does aspirin matters? Ibid.